WP
RXII

WealthPLAN Partners’s GALENA BIOPHARMA INC COM RXII Stock Holding History

WealthPLAN Partners’s Portfolio RXII Stock Details RXII Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$181 Buy
564
+364
+182% +$117 ﹤0.01% 936
2016
Q2 		$93 Buy
+200
New +$93 ﹤0.01% 2437
2015
Q4 		$294 Buy
+200
New +$294 ﹤0.01% 1603

Other funds holding RXII

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

WealthPLAN Partners's RXII Position: Q3 2016 in Review

WealthPLAN Partners increased its GALENA BIOPHARMA INC COM (RXII) stake by 182% in Q3 2016, buying an estimated $117 and bringing the position to 564 shares worth $181. The position accounts for ﹤0.01% of the portfolio, ranked #936.

WealthPLAN Partners first reported a position in RXII in Q4 2015 and has held it in 3 quarters since. The position peaked at $294 in Q4 2015. 92 funds tracked by Wall St. Rank hold RXII as of Q3 2016.

  • WealthPLAN Partners held 564 shares of GALENA BIOPHARMA INC COM worth $181 as of Q3 2016.
  • WealthPLAN Partners bought 364 GALENA BIOPHARMA INC COM shares in Q3 2016, an estimated $117.
  • GALENA BIOPHARMA INC COM made up ﹤0.01% of WealthPLAN Partners's portfolio in Q3 2016, its #936 holding.
  • WealthPLAN Partners first reported a position in GALENA BIOPHARMA INC COM in Q4 2015 and has held it in 3 quarters since.
  • WealthPLAN Partners's GALENA BIOPHARMA INC COM position peaked at $294 in Q4 2015.
  • 92 funds tracked by Wall St. Rank held GALENA BIOPHARMA INC COM as of Q3 2016.

Based on WealthPLAN Partners's 13F filing for Q3 2016, filed 9 Dec 2016.